Evidence map›Paper›PMID 35645371›Full record

ReviewProteomes2022

Insights on Proteomics-Driven Body Fluid-Based Biomarkers of Cervical Cancer.

Amrita Mukherjee, Chinmayi Bhagwan Pednekar, Siddhant Sujit Kolke, Megha Kattimani, Subhiksha Duraisamy, Ananya Raghu Burli, Sudeep Gupta, Sanjeeva Srivastava

Open access · goldAbstract readReview
In one paragraph

Review in Proteomes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Advances in the Clinical Application of High-throughput Proteomics.Exploratory research and hypothesis in medicine
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Amrita MukherjeeDepartment of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India.ORCID 0000-0003-2255-578X
Chinmayi Bhagwan PednekarDepartment of Life Science, Ramnarain Ruia Autonomous College, Mumbai 400019, India.ORCID 0000-0002-0044-8548
Siddhant Sujit KolkeDepartment of Chemistry, Indian Institute of Technology Bombay, Mumbai 400076, India.ORCID 0000-0003-0110-4429
Megha KattimaniUndergraduate Department, Indian Institute of Science, Bengaluru 560012, India.ORCID 0000-0002-4323-9076
Subhiksha DuraisamyDepartment of Human Genetics and Molecular Biology, Bharathiar University, Coimbatore 641046, India.ORCID 0000-0002-3032-6402
Ananya Raghu BurliDepartment of Chemical Engineering, Indian Institute of Technology Bombay, Mumbai 400076, India.ORCID 0000-0002-3595-511X
Sudeep GuptaAdvanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Hospital, Mumbai 400012, India.ORCID 0000-0002-6742-6378
Sanjeeva SrivastavaDepartment of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai 400076, India.ORCID 0000-0001-5159-6834
Indian Institute of Technology Bombay · INBharathiar University · INIndian Institute of Science Bangalore · INTata Memorial Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer is one of the top malignancies in women around the globe, which still holds its place despite being preventable at early stages. Gynecological conditions, even maladies like cervical cancer, still experience scrutiny from society owing to prevalent taboo and invasive screening methods, especially in developing economies. Additionally, current diagnoses lack specificity and sensitivity, which prolong diagnosis until it is too late. Advances in omics-based technologies aid in discovering differential multi-omics profiles between healthy individuals and cancer patients, which could be utilized for the discovery of body fluid-based biomarkers. Body fluids are a promising potential alternative for early disease detection and counteracting the problems of invasiveness while also serving as a pool of potential biomarkers. In this review, we will provide details of the body fluids-based biomarkers that have been reported in cervical cancer. Here, we have presented our perspective on proteomics for global biomarker discovery by addressing several pertinent problems, including the challenges that are confronted in cervical cancer. Further, we also used bioinformatic methods to undertake a meta-analysis of significantly up-regulated biomolecular profiles in CVF from cervical cancer patients. Our analysis deciphered alterations in the biological pathways in CVF such as immune response, glycolytic processes, regulation of cell death, regulation of structural size, protein polymerization disease, and other pathways that can cumulatively contribute to cervical cancer malignancy. We believe, more extensive research on such biomarkers, will speed up the road to early identification and prevention of cervical cancer in the near future.

Indexed as

CaCx—cervical cancerCIN—cervical intraepithelial neoplasiaCSCC—cervical squamous cell carcinomaCVF—cervicovaginal fluidDIGE—difference gel electrophoresisELISA—enzyme-linked immunosorbent assayHPV—Human PapillomavirusiTRAQ—isobaric tags for relative and absolute quantificationLC-MS/MS—liquid chromatography coupled with tandem mass spectrometryLFQ—label-free quantificationMALDI—TOF—matrix-assisted laser desorption/ionization—time of flightMRM—multiple reaction monitoringPRM—parallel reaction monitoring

Identifiers

PMID35645371
PMCPMC9149910
OpenAlexW4225270248

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.